Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 605,278,336
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 33,724 M
  • Annual Income, $ 12,151 M
  • 60-Month Beta 0.42
  • Price/Sales 17.58
  • Price/Cash Flow 43.84
  • Price/Book 36.48
Trade NVO with:

Options Overview Details

View History
  • Implied Volatility 29.87% ( -2.18%)
  • Historical Volatility 33.81%
  • IV Percentile 44%
  • IV Rank 25.36%
  • IV High 49.01% on 08/05/24
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 0.73
  • Today's Volume 49,787
  • Volume Avg (30-Day) 18,064
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 284,974
  • Open Int (30-Day) 266,537

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.91
  • Number of Estimates 4
  • High Estimate 0.97
  • Low Estimate 0.87
  • Prior Year 0.73
  • Growth Rate Est. (year over year) +24.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
126.13 +1.09%
on 09/20/24
139.74 -8.75%
on 08/30/24
-8.30 (-6.11%)
since 08/20/24
3-Month
118.80 +7.33%
on 08/07/24
148.15 -13.93%
on 06/25/24
-13.48 (-9.56%)
since 06/20/24
52-Week
86.96 +46.63%
on 10/03/23
148.15 -13.93%
on 06/25/24
+32.78 (+34.60%)
since 09/20/23

Most Recent Stories

More News
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?

Sanofi’s SNY stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock has also outperformed the sector and the S&P 500 index as seen in the chart...

SNY : 57.76 (-0.85%)
AZN : 78.38 (-0.66%)
NVO : 127.51 (-5.46%)
LLY : 921.49 (+0.70%)
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?

Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has also outperformed the sector as well as the S&P 500, as seen in the chart below.PFE...

PFE : 29.42 (-0.81%)
NVO : 127.51 (-5.46%)
LLY : 921.49 (+0.70%)
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks

This strategic play will take time to pay off, but it could keep growth going.

NVO : 127.51 (-5.46%)
KRRO : 36.33 (-5.64%)
MRNA : 65.69 (-3.43%)
Tap the Weight-Loss Drug Market With These ETFs

The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are...

RHHBY : 39.4500 (-0.03%)
NVO : 127.51 (-5.46%)
LLY : 921.49 (+0.70%)
HRTS : 34.68 (-1.87%)
THNR : 27.41 (-0.94%)
OZEM : 28.46 (-0.73%)
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?

Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The stock has also outperformed the sector as well as the S&P 500 as seen in the chart...

BIIB : 199.36 (-1.03%)
NVO : 127.51 (-5.46%)
LLY : 921.49 (+0.70%)
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)

Telemedicine once seemed like it was going to revolutionize healthcare.

LLY : 921.49 (+0.70%)
PFE : 29.42 (-0.81%)
NVO : 127.51 (-5.46%)
TDOC : 8.75 (-4.68%)
AMZN : 191.60 (+0.91%)
NVDA : 116.00 (-1.59%)
SFIX : 3.94 (-5.62%)
VKTX : 70.47 (+3.39%)
ALT : 7.79 (+2.91%)
RHHBY : 39.4500 (-0.03%)
HIMS : 16.30 (-3.66%)
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200

No need to break the bank to get in on these excellent companies.

NVO : 127.51 (-5.46%)
DXCM : 70.43 (-2.07%)
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More

This week, the FDA approved J&J’s JNJ Tremfya for treating an inflammatory bowel disease condition (“IBD”), ulcerative colitis. Novo Nordisk’s NVO oral obesity pill, amycretin, showed faster weight...

REGN : 1,145.03 (-0.45%)
SNY : 57.76 (-0.85%)
JNJ : 164.16 (-0.40%)
NVO : 127.51 (-5.46%)
Why Investors Plowed Into Viking Therapeutics Stock Today

The company is looking especially good after some bad news coming from a rival.

MS : 102.47 (+1.73%)
VKTX : 70.47 (+3.39%)
NVO : 127.51 (-5.46%)
LLY : 921.49 (+0.70%)
Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug

Roche RHHBY presented results of an early-stage study on its experimental obesity drug, CT-996, at the European Association for the Study of Diabetes annual meeting.CT-996 is an investigational, once-daily,...

RHHBY : 39.4500 (-0.03%)
NVO : 127.51 (-5.46%)
LLY : 921.49 (+0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 137.08
2nd Resistance Point 136.14
1st Resistance Point 135.51
Last Price 127.51
1st Support Level 133.94
2nd Support Level 133.00
3rd Support Level 132.37

See More

52-Week High 148.15
Last Price 127.51
Fibonacci 61.8% 124.78
Fibonacci 50% 117.55
Fibonacci 38.2% 110.33
52-Week Low 86.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar